The Power of Modeling: Speed, Early De-Risking, and Regulatory Success for Forward-Thinking Sponsors On-Demand Webinar The Power of Modeling: Speed, Early De-Risking, and Regulatory Success for Forward-Thinking Sponsors Learn how PBPK and QSP modeling support faster drug development by enabling smarter dose selection,…CertaraJuly 1, 2026
The Modeling Advantage: How Forward-Thinking Sponsors Are Moving Faster, De-Risking Earlier, and Winning with Regulators On-Demand Webinar The Modeling Advantage: How Forward-Thinking Sponsors Are Moving Faster, De-Risking Earlier, and Winning with Regulators Learn how PBPK and QSP modeling support regulatory confidence, accelerate drug development, and align with…CertaraMay 26, 2026
ICH M15 guideline: What the finalized guideline means for model-informed drug development Blog ICH M15 guideline: What the finalized guideline means for model-informed drug development With the release of the draft ICH M15 guidance, MIDD is no longer optional -…CertaraMarch 18, 2026
FAQs: The ICH M15 guideline and what it means for model-informed drug development Blog FAQs: The ICH M15 guideline and what it means for model-informed drug development Learn what the ICH M15 guideline means for Model-Informed Drug Development, regulatory credibility, harmonization, and…CertaraFebruary 18, 2026
Guided by Evidence: Implementing the ICH M15 Guideline for Model-Informed Drug Development (MIDD) Guide Guided by Evidence: Implementing the ICH M15 Guideline for Model-Informed Drug Development (MIDD) Prepare for ICH M15 guideline: Learn how to assess model credibility, align terminology, and strengthen…CertaraFebruary 13, 2026
Evolving Regulatory Landscape for Model Informed Drug Development (MIDD): Impact of the Draft ICH M15 Guidance On-Demand Webinar Evolving Regulatory Landscape for Model Informed Drug Development (MIDD): Impact of the Draft ICH M15 Guidance We explore the evolving regulatory landscape for Model-Informed Drug Development (MIDD), focusing on the impact…CertaraMay 23, 2025